In today’s recent session, 1.54 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have been traded, and its beta is 0.82. Most recently the company’s share price was $8.10, and it changed around $0.29 or 3.65% from the last close, which brings the market valuation of the company to $2.28B. RXRX at last check was trading at a discount to its 52-week high of $15.74, offering almost -94.32% off that amount. The share price’s 52-week low was $4.97, which indicates that the recent value has risen by an impressive 38.64% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 5.34 million shares, with the 3-month average coming to 5.63 million.
Recursion Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 6 recommended RXRX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Recursion Pharmaceuticals Inc is expected to report earnings per share of -0.35 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has been showing a green trend so far today with a performance of 3.65% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 8.16 on recent trading dayincreased the stock’s daily price by 0.74%. The company’s shares are currently down -17.90% year-to-date, but still up 13.22% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -3.05% down in the 30-day period. We can see from the shorts that 50.37 million shares have been sold at a short interest cover period of 10.51 day(s).
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 49.38% from its current value. Analyst projections state that RXRX is forecast to be at a low of $16 and a high of $16.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Recursion Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -45.16 percent over the past six months and at a -1.27% annual growth rate that is well below the industry average of 19.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 18.60% in revenue this quarter, and will report a decrease of -19.00% in the next quarter. The year-over-year growth rate is expected to be 70.90%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 33.25M in revenue for the current quarter. 6 analysts expect Recursion Pharmaceuticals Inc to make 15.83M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.53M and 10.89M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 215.70%. Forecasts for the next quarter put sales growth at 45.30%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.41%. Recursion Pharmaceuticals Inc earnings are expected to increase by 1.18% in 2024, but the outlook is positive 12.00% per year for the next five years.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in September.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.56% of Recursion Pharmaceuticals Inc shares, and 89.78% of them are in the hands of institutional investors. The stock currently has a share float of 94.06%. Recursion Pharmaceuticals Inc stock is held by 357.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 11.924% of the shares, which is about 28.14 million shares worth $211.07 million.
BAILLIE GIFFORD & CO, with 11.266% or 26.59 million shares worth $199.42 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF were the top two Mutual Funds as of Jul 31, 2024. The former held 17.13 shares worth $135.51 million, making up 6.25% of all outstanding shares. On the other hand, ARK ETF Tr-ARK Genomic Revolution ETF held roughly 9.67 shares worth around $76.48 million, which represents about 3.53% of the total shares outstanding.
